Document is current
Any future updates will be listed below
-
Authors
Parent, Cassandra https://orcid.org/0000-0002-0825-0480
Mauvieux, Benoît https://orcid.org/0000-0003-4862-6531
Lespagnol, Elodie https://orcid.org/0000-0002-1076-822X
Hingrand, Corentin https://orcid.org/0000-0003-3914-2738
Vauthier, Jean-Charles https://orcid.org/0000-0003-3796-6370
Noirez, Philippe https://orcid.org/0000-0003-4538-803X
Hurdiel, Rémy https://orcid.org/0000-0002-4711-0077
Martinet, Quentin
Delaunay, Pierre-Louis https://orcid.org/0000-0002-7421-8219
Besnard, Stéphane https://orcid.org/0000-0002-9659-8005
Heyman, Joris https://orcid.org/0000-0002-0327-7924
Gabel, Virginie https://orcid.org/0000-0002-9792-1468
Baron, Pauline
Gamelin, François-Xavier https://orcid.org/0000-0002-0188-7219
Maboudou, Patrice https://orcid.org/0000-0002-3578-7830
Rabasa-Lhoret, Rémi https://orcid.org/0000-0003-4706-5170
Jouffroy, Romain https://orcid.org/0000-0003-2616-6132
Heyman, Elsa https://orcid.org/0000-0002-9340-7592
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct05538442 at ClinicalTrials.govDocuments that mention this clinical trial
Glycaemic Effects of a 156-km Ultra-trail Race in Athletes: An Observational Field Study
https://doi.org/10.1007/s40279-024-02013-4
-
Funding
Funding for this research was provided by:
RIN TREMPLIN APEEX
International Joint Laboratory REGALE-1
Type 1 Running Team Association
Institut Universitaire de France
Hauts-de-France Regional Authority
- License Information
-
More Information
Article History
Accepted: 25 February 2024
First Online: 30 March 2024
Declarations
:
: This protocol was partly financed by the RIN TREMPLIN APEEX (Adaptation <i>Physiologiques En Environnements Extrêmes</i> – 2020/2022) supported by the Normandy Region – France and the European Regional Development Fund (ERDF). This study was undertaken as part of the project run by the International Joint Laboratory REGALE-1 (Glycemic Regulation During Exercise in Type 1 Diabetes), bringing together the URePSSS (Lille University) and IRCM (Montréal) and involving an international ‘SPORT-1’ Chair for R. Rabasa-Lhoret (I-SITE ULNE, WILL grant). This study was supported in part by grants from the Type 1 Running Team Association. EH received a grant from the <i>Institut Universitaire de France</i>, and CP received grant assistance as a doctoral student from the Hauts-de-France Regional Authority.
: The authors declare no competing interests.
: Approval institution, Ouest III Ethics Committee; ethics number, 2021-A01765-36; date of approval, 26 October 2021. Trial registration number, NCT05538442 2022-09-21, retrospectively registered. The study was performed in accordance with the ethical standards in the Declaration of Helsinki.
: All participants were fully informed of the nature and possible risks of the experimental procedures before their written informed consent was obtained.
: Not applicable.
: Not applicable.
: All authors read and approved the final version. EH and BM designed the experiments. FXG and RRL gave advice on some methodological points. CP, EL, EH, JCV, RH, PLD, SB, PN, VG, PB, QM, and RJ carried out the experiments and collected the data. PM performed blood analyses. EH and CP analysed the data. JH created algorithms for analyses of glycaemic excursions and variability. BM and CH recruited the participants, organized the protocol and the race, and submitted the protocol to the ethics committee. EH and CP wrote the manuscript. All authors were involved in reviewing the manuscript. EH has guaranteed the integrity of the study throughout its duration and, as such, had full access to data and takes responsibility for the integrity of the data and accuracy of the data analysis.
: All data related to this article are available on platform ().
